Commercializing Oncology Medicines that Benefit Human Health

Admune Therapeutics LLC, a clinical stage biotechnology company, was founded by a highly experienced team of scientists and business people with a proven track record in producing successful biomedical products. Admune Therapeutics is affiliated with Marine Polymer Technologies, Inc. (MPT), a provider of ground-breaking medical solutions focused in the areas of hemostasis and wound healing.

Admune Therapeutics is engaged in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to conduct R&D and commercialize innovative cytokine cancer therapies that will benefit human health. Through this collaboration, our company is moving forward with a Phase I in-human study of Admune‚Äôs lead compound, heterodimeric IL-15:IL-15Ra, for cancer immunotherapy. The trial will be conducted through the National Cancer Institute at the National Institutes of Health.  

Cancer immunotherapy or immuno-oncology is a rapidly evolving biotech field and Admune is at the forefront of this research. For more than a decade, we have worked on developing innovative cytokine cancer therapies for treating cancer patients. Admune Therapeutics uses proprietary technologies to advance new immunotherapeutics to the clinic.

Admune Therapeutics LLC
107 Water Street
Danvers, MA 01923

Tel: 888-666-2560
Email: information@admune.com